Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Portfolio Pulse from Happy Mohamed
Celularity Inc. (NASDAQ:CELU), a biotechnology company, has announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron). The agreement will support the research of Regeneron's allogeneic cell therapy candidates, with an initial focus on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron. The research will take place at Celularity's facility in Florham Park, N.J.
August 29, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The agreement with Regeneron is a significant milestone for Celularity, recognizing its expertise in cellular therapies research. This could potentially lead to more industry collaborations in the future.
The collaboration with a renowned company like Regeneron validates Celularity's expertise in the field of cellular therapies. This could potentially attract more collaborations, positively impacting the company's growth and stock value.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Regeneron's collaboration with Celularity will support the research of its allogeneic cell therapy candidates, potentially accelerating the development and enhancing the effectiveness of its CAR T-cell therapy.
The collaboration with Celularity provides Regeneron with additional research support, potentially accelerating the development of its cell therapy candidates. This could lead to faster product development and market entry, positively impacting its stock value.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100